How should a Crohn's disease flare be treated?

Treatment of Crohn's Disease Flare

For moderate to severe Crohn's disease flares, start oral prednisone 40-60 mg daily to induce remission, and evaluate response within 2-4 weeks. 1

Treatment Algorithm Based on Disease Severity

Mild Ileocolonic or Right-Sided Disease

• First-line: Oral budesonide 9 mg daily 1
• Assess response at 4-8 weeks
• Budesonide has fewer side effects than prednisone but is marginally less effective and only appropriate for isolated ileo-caecal disease 2

Mild Colonic Disease Only

• Consider sulfasalazine 4-6 g/day 1
• Evaluate response at 2-4 months
• Do NOT use mesalazine (5-ASA) - it is ineffective for Crohn's disease 3, 4

Moderate to Severe Disease

• Oral prednisone 40-60 mg daily (strong recommendation) 1
• Taper gradually over 8 weeks once remission achieved - rapid reduction causes early relapse 2
• Assess response at 2-4 weeks; if inadequate, escalate therapy

Severe Disease Requiring Hospitalization

• IV corticosteroids: methylprednisolone 40-60 mg/day or hydrocortisone 400 mg/day 2, 1
• Add IV metronidazole to distinguish active disease from septic complications 2
• Evaluate response within 1 week 1
• Supportive care includes:
  • IV fluids and electrolyte replacement
  • Blood transfusion to maintain hemoglobin >10 g/dl
  • Subcutaneous heparin for thromboembolism prophylaxis
  • Nutritional support if malnourished 2

Early Biologic Therapy for High-Risk Patients

For moderate to severe disease with poor prognostic factors, anti-TNF therapy (infliximab or adalimumab) should be first-line treatment rather than corticosteroids. 1

Poor prognostic factors include:

• Young age at onset
• Perianal disease
• Extensive disease
• Deep ulcerations
• Prior corticosteroid use at presentation
• Stricturing or penetrating disease pattern

Anti-TNF Therapy Details

• Combination therapy with thiopurine is superior to monotherapy for infliximab 3, 1
• Assess response at 8-12 weeks 1
• Continue maintenance therapy if response achieved 1

Critical Pitfalls to Avoid

1. Never use corticosteroids for maintenance - they are ineffective and cause harm 1
2. Do not use 5-ASA/mesalazine - multiple guidelines confirm no benefit in Crohn's disease 3, 4
3. Do not delay escalation - if no response to initial therapy within specified timeframes, modify treatment immediately
4. Avoid rapid steroid taper - taper over 8 weeks minimum to prevent early relapse 2

Concurrent Maintenance Planning

While treating the acute flare, simultaneously plan maintenance therapy:

• Azathioprine 1.5-2.5 mg/kg/day or mercaptopurine 0.75-1.5 mg/kg/day for patients achieving remission with corticosteroids 2, 5
• Parenteral methotrexate 15-25 mg weekly for corticosteroid-dependent/resistant disease 2, 1
• Continue anti-TNF therapy if used for induction 1

The 2019 Canadian and British guidelines 1, 3, 1 represent the most recent high-quality evidence and emphasize early aggressive therapy in moderate-severe disease to prevent complications and bowel damage, moving away from the traditional step-up approach for higher-risk patients.